Knight Therapeutics Inc., (TSX: GUD) ('Knight') a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Argentine affiliate, Laboratorio LKM S.A., and its Mexican affiliate, ...

The newly approved mosunetuzumab for relapsed/refractory follicular lymphoma improves clinic efficiency and patient experience, says Zahra Mahmoudjafari, PharmD, MBA, BCOP. She also explained how the ...

Subcutaneous mosunetuzumab simplifies the delivery of the bispecific therapy for patients with relapsed/refractory follicular lymphoma, says Zahra Mahmoudjafari, PharmD, MBA, BCOP.

Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltda. has received approval from ...

Epigenetic therapies are offering a more targeted way to treat some lymphomas by changing how genes are turned on or off ...

Genmab A/S (NASDAQ:GMAB) executives highlighted a “very strong year” in 2025 and outlined a catalyst-heavy 2026 that could ...

ADC Therapeutics (NYSE:ADCT) is one of the best growth stocks to buy right now. On March 10, ADC Therapeutics reported its ...

Welcome to Knight Therapeutics Fourth Quarter and Year-end 2025 Results Conference Call. Before turning the call over to Samira Sakhia, President and CEO of Knight, listeners are reminded that ...

Knight Therapeutics Inc. (TSX: GUD) ("Knight" or “the Company”), a pan-American (ex-US) specialty pharmaceutical company, today reported financial results for its fourth quarter and year ended ...

In this article, we will discuss the 13 Best Growth Stocks to Buy Right Now. On March 16, Chief Investment Strategist at Hightower Stephanie Link and Chief Investment Officer at NFJ Investment Group ...

Detailed price information for Bioinvent International Ab (BOVNF) from The Globe and Mail including charting and trades.

The recent FDA approval of teclistamab (Tecvayli) and daratumumab and hyaluronidase-fihj (Darzelex Faspro) marks a major ...